Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

The New England journal of medicine - 28 Oct 2010

Butrynski James E, D'Adamo David R, Hornick Jason L, Dal Cin Paola, Antonescu Cristina R, Jhanwar Suresh C, Ladanyi Marc, Capelletti Marzia, Rodig Scott J, Ramaiya Nikhil, Kwak Eunice L, Clark Jeffrey W, Wilner Keith D, Christensen James G, Jänne Pasi A, Maki Robert G, Demetri George D, Shapiro Geoffrey I

Abstract excerpt

Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abdominal Neoplasms
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Share to Receptors, Growth Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 20979472
DOI: 10.1056/NEJMoa1007056
PMCID: PMC3014292

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.PMID 20979472Read ↗

Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to CrizotinibSemantic proximity Read ↗

Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsSemantic proximity Read ↗

Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.Semantic proximity Read ↗

ALK-Negative Lung Inflammatory Myofibroblastic Tumor in a Young Adult: a Case Report and Literature Review of Molecular AlterationsSemantic proximity Read ↗

An Inflammatory Myofibroblastic Tumor With a Novel ALKV1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

ALK‑G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case reportSemantic proximity Read ↗

Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic CancerSemantic proximity Read ↗

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Semantic proximity Read ↗

Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET RearrangementSemantic proximity Read ↗

Crizotinib combined with bronchoscopic interventional treatment in ALK-positive Inflammatory myofibroblastic tumor of left main stem bronchus: a case reportSemantic proximity Read ↗

Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.Semantic proximity Read ↗

Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.